Drug Database
Back to search

Netherlands· NL-53d71a45959c

Emtricitabine/Tenofovirdisoproxil Teva 200mg/245 mg, filmomhulde tabletten

A tenofovir disoproxil and emtricitabine product containing emtricitabine + tenofovirdisoproxilfosfaat, registered in Netherlands by Teva Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEmtricitabine/Tenofovirdisoproxil Tev…ATCJ05AR03REGISTER NO.NL-53d71a45959cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about emtricitabine + tenofovirdisoproxilfosfaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tenofovir disoproxil and emtricitabine is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR03 (tenofovir disoproxil and emtricitabine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search tenofovir disoproxil and emtricitabine products by name

Tenofovir disoproxil and emtricitabine · ATC J05AR03

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
EMTRICITABINE + TENOFOVIRDISOPROXILFOSFAAT
Manufacturer
Teva Nederland B.V.
Country
Netherlands (NL)
ATC code
J05AR03
ATC class
Tenofovir disoproxil and emtricitabine
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    117050

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

9 interactions on record for tenofovir disoproxil and emtricitabine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tenofovir disoproxil and emtricitabine against other medicinesHow interaction checks work

Tenofovir disoproxil and emtricitabine · interactions on record

9 records

9 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same class

Other records under J05AR03

Tenofovir disoproxil and emtricitabine, as other registers publish it.

All tenofovir disoproxil and emtricitabine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b7dbfced-b03e-4f7e-9bd2-56d46142da37
GET /v1/drugs/b7dbfced-b03e-4f7e-9bd2-56d46142da37?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h117050_smpc.pdf",
  "strength": null,
  "atc_label": "Tenofovir Disoproxil And Emtricitabine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg117050",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "MACROGOL 3350",
    "MANNITOL (D-) (E 421)",
    "NATRIUMSTEARYLFUMARAAT",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "EMTRICITABINE",
    "TENOFOVIRDISOPROXILFOSFAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h117050.pdf",
  "authorised_at": "2016/09/29",
  "procedure_number": "NL/H/3432/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "117050",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about tenofovir disoproxil and emtricitabine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console